The newest class of antiretrovirals for all persons living with HIV are the integrase strand
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …

Background The human immunodeficiency virus (HIV) causes movement disorders in
persons living with HIV (PLH). Objectives and methods We conducted a systematic review …

International Journal of Epidemiology, 2023, e241–e252 https://doi. org/10.1093/ije/dyad083
Advance Access Publication Date: 4 July 2023 Cohort Profile responsible unit of HIV/STI …

Page 1 Pharmacology Research And Textbook 2 Chapter1: HIV-1 Integrase Inhibitors and
Neurodevelopment Chapter2: Coenzyme Q10 Chapter3: Ferroptosis Author in Chief …

Children born to mothers, with or at risk, of human immunodeficiency virus type-1 (HIV-1)
infection are on the rise due to affordable access of antiretroviral therapy (ART) to pregnant …

Introduction Second-generation integrase strand transfer inhibitors such as bictegravir (BIC)
and dolutegravir (DTG) are the standard of care for starting therapy in people living with HIV …

The aim of this retrospective cohort study was to compare safety, efficacy and rates and
reasons of discontinuation of the 3 currently approved integrase strand transfer inhibitors …

Background: Despite increased integrase strand transfer inhibitor (INSTI) use, limited large-
scale, real-life data exists on INSTI uptake and discontinuation. Setting: International …

Clinical trials of dual regimen dolutegravir/lamivudine (DOL/3TC) demonstrated potent
efficacy and favorable safety in both antiretroviral therapy-naïve and-experienced patients …

Objectives Tenofovir disoproxil fumarate (TDF) is associated with reduced bone mineral
density (BMD). We evaluated changes in BMD in women who switched from TDF …